Home Medicine Association between plasma thiols and immune activation marker neopterin in stable coronary heart disease
Article
Licensed
Unlicensed Requires Authentication

Association between plasma thiols and immune activation marker neopterin in stable coronary heart disease

  • Katharina Schroecksnadel , Roland B. Walter , Guenter Weiss , Michael Mark , Walter H. Reinhart and Dietmar Fuchs
Published/Copyright: February 26, 2008

Abstract

Background: Studies have associated elevated plasma levels of the thiols homocysteine and cysteine with an increased risk of atherosclerosis. Their relationship with systemic inflammatory parameters and sclerosis scores was investigated in this study.

Methods: Total homocysteine, total cysteine, neopterin and C-reactive protein (CRP) concentrations were measured in blood samples of 242 patients undergoing elective coronary angiography. A total of 181 patients had coronary artery disease (CAD), as defined by occlusion of >75% of at least one of the three main coronary arteries, and 61 subjects did not have relevant coronary stenoses.

Results: Total cysteine concentrations were higher in patients suffering from coronary artery sclerosis with stepwise increases relative to the extent of coronary artery sclerosis (p<0.001). In contrast, neither total homocysteine nor the inflammatory markers, CRP and neopterin, differed between patients and controls. However, total homocysteine concentrations correlated with total cysteine (r=0.468) and neopterin concentrations (r=0.290), as well as serum creatinine (r=0.226; all p<0.001), the latter indicating a dependence of total homocysteine concentrations on kidney function. Total cysteine concentrations were associated with increased neopterin levels (r=0.231, p<0.001).

Conclusions: Total cysteine concentrations were well suited to estimate the extent of coronary artery sclerosis, while in our study of stable CAD patients total homocysteine was not increased compared to controls. The association between homocysteine, cysteine and parameters of immune activation and inflammation in our study suggests that these markers of CAD may be interdependent.

Clin Chem Lab Med 2008;46:648–54.


Corresponding author: Dr. Dietmar Fuchs, Division of Biological Chemistry, Biocenter, Innsbruck Medical University, Fritz Pregl Strasse 3, 6020 Innsbruck, Austria Phone: +43-512-9003-70350, Fax: +43-512-9003-73330,

Received: 2007-10-31
Accepted: 2007-12-18
Published Online: 2008-02-26
Published in Print: 2008-05-01

©2008 by Walter de Gruyter Berlin New York

Articles in the same Issue

  1. Editorial
  2. Comparability of tumor marker immunoassays: still an important issue for clinical diagnostics?
  3. Review
  4. The diagnostic role of autoantibodies in the prediction of organ-specific autoimmune diseases
  5. Validation and Outcome Studies
  6. Alternative antibody for the detection of CA125 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access® OV Monitor assay on the UniCel® DxI 800 Immunoassay System
  7. Alternative antibody for the detection of CA19-9 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access® GI Monitor assay on the UniCel® DxI 800 Immunoassay System
  8. Alternative antibody for the detection of CA15-3 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access® BR Monitor assay on the UniCel® DxI 800 Immunoassay System
  9. Toward metrological traceability in the determination of prostate-specific antigen (PSA): calibrating Beckman Coulter Hybritech Access PSA assays to WHO standards compared with the traditional Hybritech standards
  10. Multicentre evaluation of a new point-of-care test for the determination of CK-MB in whole blood
  11. Down's syndrome screening: population statistic dependency of screening performance
  12. General Clinical Chemistry and Laboratory Medicine
  13. Association between plasma thiols and immune activation marker neopterin in stable coronary heart disease
  14. Role for mitochondrial uncoupling protein-2 (UCP2) in hyperhomocysteinemia and venous thrombosis risk?
  15. Plasma procalcitonin measured by time-resolved amplified cryptate emission (TRACE) in liver transplant patients. A prognosis marker of early infectious and non-infectious postoperative complications
  16. Interactions of lipoprotein(a) with diabetes mellitus, apolipoprotein B and cholesterol enhance the prognostic values for coronary artery disease
  17. Association of thyroid stimulating hormone and coronary lipid risk factors with lipid peroxidation in hypothyroidism
  18. The effect of the mode of delivery on the maternal-neonatal carnitine blood levels and antioxidant status
  19. Time to reconsider the clinical value of immunoglobulin G4 to foods?
  20. Reference Values
  21. Determination of reference intervals for 26 commonly measured biochemical analytes with consideration of long-term within-individual variation
  22. Beverage-specific effects of ethanol consumption on its biological markers
  23. Limits of preservation of samples for urine strip tests and particle counting
  24. Reference ranges and diagnostic thresholds of laboratory markers of cardiac damage and dysfunction in a population of apparently healthy black Africans
  25. Letters to the Editor
  26. External quality assessment schemes for real-time PCR: a statistical procedure to corrective actions
  27. Application of two different microarray-based copy-number detection methodologies – array-comparative genomic hybridization and array-multiplex amplifiable probe hybridization – with identical amplifiable target sequences
  28. Criticism to the article: “Toward standardization of carbohydrate-deficient transferrin (CDT) measurements: I. Analyte definition and proposal of a candidate reference method.” Authors: J.O. Jeppsson et al. Clin Chem Lab Med 2007;45(4):558–562
  29. Standardization of carbohydrate-deficient transferrin: reply to the letter by Tagliaro and Bortolotti
  30. Comment on: Bellini C, Serra G, Risso D, Mazzella M, Bonioli E. Reliability assessment of glucose measurement by HemoCue analyser in a neonatal intensive care unit. Clin Chem Lab Med 2007;45(11):1549–54
  31. Reliability assessment of glucose measurement by HemoCue analyzer in a neonatal intensive care unit: reply to Dr. Joakim Hagvik
Downloaded on 10.2.2026 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2008.121/html
Scroll to top button